Biovaxys Technology Financials
| BVAXF Stock | USD 0.05 0.0004 0.80% |
With this module, you can analyze Biovaxys financials for your investing period. You should be able to track the changes in Biovaxys Technology individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Biovaxys |
Understanding current and past Biovaxys Technology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biovaxys Technology's financial statements are interrelated, with each one affecting the others. For example, an increase in Biovaxys Technology's assets may result in an increase in income on the income statement.
The data published in Biovaxys Technology's official financial statements typically reflect Biovaxys Technology's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biovaxys Technology's quantitative information. For example, before you start analyzing numbers published by Biovaxys accountants, it's essential to understand Biovaxys Technology's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Biovaxys Technology Stock Summary
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | CA09076M1014 |
| Business Address | 905 West Pender |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.biovaxys.com |
| Phone | 604 262 8835 |
| Currency | USD - US Dollar |
Biovaxys Technology Key Financial Ratios
There are many critical financial ratios that Biovaxys Technology's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Biovaxys Technology Corp reports annually and quarterly.| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Number Of Employees | 17 | |||
| Beta | -0.59 | |||
| Z Score | -7.8 |
Biovaxys Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biovaxys Technology's current stock value. Our valuation model uses many indicators to compare Biovaxys Technology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biovaxys Technology competition to find correlations between indicators driving Biovaxys Technology's intrinsic value. More Info.Biovaxys Technology Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biovaxys Technology's earnings, one of the primary drivers of an investment's value.Biovaxys Technology Corp Systematic Risk
Biovaxys Technology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biovaxys Technology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Biovaxys Technology Corp correlated with the market. If Beta is less than 0 Biovaxys Technology generally moves in the opposite direction as compared to the market. If Biovaxys Technology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biovaxys Technology Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biovaxys Technology is generally in the same direction as the market. If Beta > 1 Biovaxys Technology moves generally in the same direction as, but more than the movement of the benchmark.
Biovaxys Technology November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biovaxys Technology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biovaxys Technology Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biovaxys Technology Corp based on widely used predictive technical indicators. In general, we focus on analyzing Biovaxys OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biovaxys Technology's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.92 | |||
| Information Ratio | 0.0282 | |||
| Maximum Drawdown | 37.09 | |||
| Value At Risk | (8.24) | |||
| Potential Upside | 7.66 |
Complementary Tools for Biovaxys OTC Stock analysis
When running Biovaxys Technology's price analysis, check to measure Biovaxys Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovaxys Technology is operating at the current time. Most of Biovaxys Technology's value examination focuses on studying past and present price action to predict the probability of Biovaxys Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovaxys Technology's price. Additionally, you may evaluate how the addition of Biovaxys Technology to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |